Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT03023371
Recruiting Observational

National Registry of IgG4-RD in China

NCT03023371 · tracked via the Priya Life Science China tracker
Sponsor
Peking Union Medical College Hospital
Phase
Observational
Started
2016-12
Last updated
2017-01-24

Condition(s) studied

IgG4-Related Disease

Study summary

The aim of this study is to establish a nation-wide cohort study of IgG4-related disease (IgG4-RD) in China.

Methods: All the patients fulfilling diagnostic criteria of IgG4-RD (2011) would be enrolled from multi-centers around China. A online database system has been established.

Endpoints: The primary endpoint is to investigate the clinical manifestations of Chinese IgG4-RD patients; the secondary endpoints including the demographic features,laboratory characteristics, immunological tests, imaging and pathological features, in addition, the treatment and prognosis of the disease.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Conforming to the diagnostic criteria of IgG4-RD (2011); Exclusion Criteria: * Excluding other mimicing IgG4-RD, including tumors, vasculitis and sarcoidosis.

Primary outcome measure(s)

  • Organ involvements of Chinese IgG4-RD patients — 5 years
    To calculate the percentage of organ involvements in at least 900 patients.

Trial sites (1)

FacilityCityRegionStatus
Peking Union Medical College Hospital Beijing Beijing Municipality Recruiting

More Peking Union Medical College Hospital trials in China

Spectral CT in Radiotherapy for Cervical Cancer Recruiting
Bowel Sound in Predicting the Severity of Acute Pancreatitis: Protocol of a Prospective, Multi-center Study Recruiting
TIME in Immunotherapy Combined With nCRT for Rectal Cancer Active, not recruiting
A Prospective Cohort Study of IRPF in China Recruiting
Risk Stratification for Abdominal Emergency Surgery: a Cohort Study Active, not recruiting

Other trials for the same condition

Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease Recruiting
A Prospective Cohort Study of IgG4RD in China Recruiting
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03023371 on ClinicalTrials.gov ↗ ← All trials in China